Storage and handling
Protect from light and heat.
Protect from light and heat.
Homeopathic Decongestant / Bronchodilator Medicine
5 CAPSULES
For temporary relief of flu symptoms.
1 capsule contains 330 mg Mycobacterium phlei 6X in a base of lactose.
One capsule once weeky, either before breakfast or at bedtime.
If symptoms persist more than a few days, contact a licensed practitioner. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before taking this product.
Keep this and all medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.
Protect from light and heat.
Do not use this product if imprinted inner blister pack is broken or if imprinted security strip on carton ist torn.
Made in Germany.
Distributed by:
SANUM USA Corp.
1465 Slater Road
Ferndale, WA 98248
Manufactured by:
Sanum-Kehlbeck
GmbH & Co. KG
Rev. 07/2004
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60681-5403-2 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-dc32-621f-e053-dbdaa90a74ad | Pleo™ Ut "S" CAPSULES 6X |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60681-5403-2 | Pleo Ut S | 5 in 1 BLISTER PACK | CAPSULE | 5 | 1 | |
| 60681-5403-2 | Pleo Ut S | 1 in 1 CARTON | CAPSULE | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60681-5403 | PLEO UT S (MYCOBACTERIUM PHLEI) CAPSULE [SANUM KEHLBECK GMBH & CO. KG] | 1 | Legacy NDC, 2 package rows | 20110113_ba5efeb5-c7f3-482f-ad93-b2aff5de7db8.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| mycobacterium phlei | ACTIVE INGREDIENT | T67520T45F | 1 | |
| mycobacterium phlei | ACTIVE MOIETY | T67520T45F | 1 | |
| lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60681-5403 | 60681-5403-2 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| mycobacterium phlei | T67520T45F | ACTIB |
| lactose | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 04ec67e5-8994-404b-a697-73c4bf70e9e1 | ba5efeb5-c7f3-482f-ad93-b2aff5de7db8 | 2009-10-08 | Warnings | 04ec67e5-8994-404b-a697-73c4bf70e9e1 ba5efeb5-c7f3-482f-ad93-b2aff5de7db8 |
Adverse event summaries are temporarily unavailable. Other product information remains available.